Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more
Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
Dana-Farber breast oncologists, surgeons, and researchers participated in the 2019 San Antonio Breast Cancer symposium. Our faculty shared results from clinical trials and recent research studies, and led a variety of conversations on improving breast cancer care.
Catch up on Twitter: #SABCS19
Schedule of Presentations by Dana-Farber Faculty As leaders in breast cancer research, physicians and scientists from Dana-Farber Cancer Institute participated in workshops, general sessions, and forums at SABCS 2019. View the schedule of presentations by Dana-Farber faculty for Tuesday through Friday
As leaders in breast cancer research, physicians and scientists from Dana-Farber Cancer Institute participated in workshops, general sessions, and forums at SABCS 2019.
View the schedule of presentations by Dana-Farber faculty for Tuesday through Friday
Presentations include:
Dana-Farber's Eric P. Winer, MD, Explains Results of HER2CLIMB TrialThis trial looked at a new breast cancer drug called tucatinib, combined with standard therapies.
Ian Krop, MD, PhD, Presents Results from the Phase 2 DESTINY-01 StudyThis study showed how a new antibody-drug conjugate helped prevent cancer progression in women with advanced HER2+ breast cancer.
Sara Tolaney, MD, MPH, Presents Results from the Phase 2 ATEMPT Trial The Phase 2 ATEMPT trial explored a less toxic therapy for early state HER2+ breast cancer.
For SABCS media inquiries, contact John Noble, Media Relations Manager, at johnw_noble@dfci.harvard.edu.